CLINICAL_TRIALS
trial_result
· 2026-06-25
Clinical Trial Results: Obinutuzumab in Primary FSGS [Phase 2]
Summary
Phase 2 trial results evaluating obinutuzumab for primary focal segmental glomerulosclerosis have been completed and results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Mayo Clinic | Conditions: Primary Focal Segmental Glomerulosclerosis | Phase 2 | Status: COMPLETED | Results posted: 2026-06-25